SCHEMBL2097607

SCHEMBL2097607

FC(F)(F)Oc1ccc(-c2nc[c]s2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 6/20 0.41
KCNH2 Q12809 3/20 0.41
SCN10A Q9Y5Y9 2/20 0.41
SCN1A P35498 1/20 0.41
SCN9A Q15858 1/20 0.41
SCN2A Q99250 1/20 0.41
SCN8A Q9UQD0 1/20 0.41
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
NISCH Q9Y2I1 1/20 0.40
IDO1 P14902 1/20 0.39
ALPI P09923 1/20 0.39
CYP1A2 P05177 1/20 0.38
CHRNA7 P36544 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
NOTUM Q6P988 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147254 0.77 KIF11 (0.44) KDM4ENPC1ALDH1A1GAAMAPT
SCHEMBL2094048 0.77 GPR3 (0.41) SCN5ASCN9ASCN2ANPC1GAA
SCHEMBL5539715 0.74 KDM4E (0.41) KDM4ENPC1ALDH1A1RAB9AALOX5
SCHEMBL468075 0.71 PDPK1 (0.52) SCN5AKCNH2SCN10ASCN1ASCN9A
SCHEMBL5543661 0.71 PDPK1 (0.41) KDM4ENPC1ALDH1A1MAPTRAB9A
SCHEMBL2091591 0.71 METAP2 (0.38)
SCHEMBL2094976 0.70 NISCH (0.40) SCN5AKCNH2SCN10ASCN1ASCN9A
SCHEMBL1723225 0.70 KDM4E (0.43) SCN5AKCNH2SCN10ASCN1ASCN9A
SCHEMBL2752145 0.70 NOTUM (0.44) NOTUM
SCHEMBL3664986 0.69 CLK4 (0.57) SCN5AKCNH2SCN10ASCN1ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 SCN5A 3182/4885KCNH2 3121/4885SCN10A 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.